Adherium Ltd (ASX: ADR) Share Price and News

Mr Panaccio is also a Non-executive Director of Unison Housing Limited and Non-executive Chairman of Magellan Stem Cells Pty Ltd. Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology for ten years to 2001, the Chief Executive Officer of Monash IVF until 2009 and the Executive Chairman of Health Networks Australia until 2017. He is member of risk committee.

Dr Hunter has experience in commercialising medical device technologies. He co-founded Angiotech Pharmaceuticals in 1992 and assumed the position of CEO in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through its IPO and listing on the Toronto Stock Exchange and NASDAQ. Dr Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor, including the TAXUS Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug Eluting Stent, the Quill barbed wound closure device and the Persona IQ 'smart' knee replacement. Combined, these products have generated revenues of over $12 billion and have helped the lives of over 50 million patients globally. He is currently the Founder, President and CEO of Canary Medical Inc. which develops and commercializes implantable sensors and data informatics for medical devices. He was formerly the CEO Correvio Pharma Corp (NASDAQ: CORV). Dr Hunter is Chairman of Tensive, a woman's health medical device company and an Industry Expert Advisor for BioScience Managers (manager of a major shareholder in Adherium). He has previously served as a director of Epirus Biopharmaceuticals (NASDAQ: EPRS), Aspriva (NASDAQ: ASPV), Anormed (NASDAQ: ANOR), and Zalicus (NASDAQ: ZLCS). Dr Hunter served as a practising physician in British Columbia for five years.

Mr McHarrie is a company director and adviser in the health and life sciences sectors with over 30 years of experience. He was formerly with Telethon Kids Institute in Perth, Western Australia, for 15 years, where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. Prior to joining Telethon Kids, Mr McHarrie was a Senior Manager at Deloitte in London before moving to Rothschild Asset Management as Assistant Director of the Bioscience Unit, a life sciences private equity group investing in early-stage biotechnology and healthcare companies. Outside his role at Adherium, he is currently an advisor to BioScience Managers (manager of a major shareholder in Adherium). Mr McHarrie was previously a director at AusCann Group Holdings Ltd and Pharmamark Nutrition Pty Ltd. He is chair of risk committee.

Mr Cook was previously interim CEO of Adherium Limited in 2019 and is an investor in the Australian life science sector. He was formerly head of the life science private equity team at Rothschild Asset Management in the UK. At Rothschild, Mr Curnock Cook was responsible for the launch of the dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook has specialised in creating value in emerging biotech enterprises, through participation with management. He has served on over 40 boards in roles, including chair of private and public biotechnology companies listed on NASDAQ, AMEX, LSE, TSX and ASX. He is currently Managing Director of BioScience Managers (manager of a shareholder in Adherium), and sits on the board of Rex Bionics Pty Ltd, Humanetix Ltd, Marine Department Ltd, Cambridge Respiratory Innovations Ltd, and Sea Dragon Ltd.

Mr Baran has over 35 years of experience in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a shareholder. In addition to his role at Trudell, Mr Baran is an investor in and Director of several medical device and e-health/connected care companies including Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc. Mr Baran has been responsible for the marketing of new drug delivery technologies to medical opinion leaders and pharmaceutical companies. This has included collaboration with business and clinical partners in the design and co-ordination of clinical studies. He has also been granted US and international patents for medical devices for drug delivery and minimally invasive surgery. Mr Baran currently serves on the Advisory Board of the Lawrence National Centre for Policy and Management.

-

-

-

-

-

-